Recurrence of aneurysmal bone cysts in young children: a multicentre study.
Some authors have reported that the clinical and pathologic behaviour of aneurysmal bone cysts (ABCs) is more aggressive in younger patients and that younger patients have more tumour recurrence. The authors carried out a retrospective, multicentred paediatric population-based analysis of 21 patients (14 boys and seven girls), 5 years of age or younger, with primary ABCs. Only patients with a minimum follow-up of 2 years were included. The most common operation was curettage (14 cases). Methylprednisolone acetate injection was used in two cases (failure in the initial diagnosis before biopsy) with negative results. An Ethibloc (Ethnor Laboratories/Ethicon, Norderstedt, Germany) injection was employed in four cases. There were five recurrences. Three lesions recurred once, one lesion recurred three times and one recurred six times. These recurrences occurred in two cases after methylprednisolone acetate injection, after Ethibloc (Ethnor Laboratories/Ethicon) injection (one case) and, after curettage (two cases). ABCs in children, 5 years of age or younger, do not seem to be more aggressive than in older children. Curettage is a surgical procedure that can be used even in young children. Of course, recurrence is always possible but the recurrence rate is not unacceptable. More aggressive operative intervention does not appear to be indicated.
Cottalorda
Jérôme
J
Department of Orthopaedic Paediatric Surgery, University of Medicine, Saint-Etienne, France. j.cotta@mageos.com
Kohler
Rémi
R
Chotel
Franck
F
de Gauzy
Jérôme Sales
JS
Lefort
Gérard
G
Louahem
Djamel
D
Bourelle
Sophie
S
Diméglio
Alain
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017824:Bone Cysts, Aneurysmal / Q000150:complications* / Q000000981:diagnostic imaging / Q000628:therapy*; D002675:Child, Preschool; D003475:Curettage; D003973:Diatrizoate / Q000627:therapeutic use; D004338:Drug Combinations; D005227:Fatty Acids / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007267:Injections; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D011409:Propylene Glycols / Q000627:therapeutic use; D011859:Radiography; D012008:Recurrence; D012189:Retrospective Studies; D012597:Sclerosing Solutions / Q000627:therapeutic use; D015028:Zein / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D000077555:Methylprednisolone Acetate; D015028:Zein; C020481:alcoholic prolamine solution; D008775:Methylprednisolone